Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. (18th December 2018)

• Record Type: Journal Article
• Authors: Prasad, Kameshwar; Siemieniuk, Reed; Hao, Qiukui; Guyatt, Gordon; O'Donnell, Martin; Lytvyn, Lyubov; Heen, Anja Fog; Agoritsas, Thomas; Vandvik, Per Olav; Gorthi, Sankar Prasad; Fisch, Loraine; Jusufovic, Mirza; Muller, Jennifer; Booth, Brenda; Horton, Eleanor; Fraiz, Auxiliadora; Siemieniuk, Jillian; Fobuzi, Awah Cletus; Katragunta, Neelima; Rochwerg, Bram
• Is Part Of: BMJ. Volume 363(2018)
• Publication Date: 2018-12-18
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Periodicals; 610
• DOI: 10.1136/bmj.k5130
• Languages: English
• ISSNs: 0007-1447

Abstract

Abstract : What is the role of dual antiplatelet therapy after high risk transient ischaemic attack or minor stroke? Specifically, does dual antiplatelet therapy with a combination of aspirin and clopidogrel lead to a greater reduction in recurrent stroke and death over the use of aspirin alone when given in the first 24 hours after a high risk transient ischaemic attack or minor ischaemic stroke? An expert panel produced a strong recommendation for initiating dual antiplatelet therapy within 24 hours of the onset of symptoms, and for continuing it for 10-21 days. Current practice is typically to use a single drug: